Opus Genetics logo

Opus Genetics (IRD) Q1 2025 Annual Earnings

IRD·Reported May 15, 2025·Before market open

Opus Genetics reported Q1 2025 revenue of $4.4M (+155.4% YoY), beat analyst consensus of $3.4M by $970.0K. Diluted EPS came in at $-0.32 (-10.3% YoY), beat the $-0.34 consensus by $0.02.

Revenue
$4.4Mbeat by $970.0K
Consensus: $3.4M
Diluted EPS
$-0.32beat by $0.02
Consensus: $-0.34
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001140361-25-011410

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Opus Genetics's Q1 2025 earnings report.

Opus Genetics (IRD) reported Q1 2025 earnings on May 15, 2025 before market open.

Opus Genetics reported revenue of $4.4M and diluted EPS of $-0.32 for Q1 2025.

Revenue beat the consensus estimate of $3.4M by $970.0K. EPS beat the consensus estimate of $-0.34 by $0.02.

Compared to the same quarter a year prior, revenue grew 155.4% from $1.7M a year earlier and diluted EPS declined 10.3% from $-0.29.

You can read the 10-K periodic report (0001140361-25-011410) directly on SEC EDGAR. The filing index links above go to sec.gov.